Prognostic value of MIB-1, E-cadherin, and CD44 in pediatric chordomas

Pediatric and Developmental Pathology

Volumn 8, Issue 3, 2005, Pages 362-368

  Saad, Aly G ^a   Collins, Margaret H ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

CD44; Chordomas; E cadherin; MIB 1

Indexed keywords

HERMES ANTIGEN; KI 67 ANTIGEN; UVOMORULIN;

ADOLESCENT; ARTICLE; CELL PROLIFERATION; CHORDOMA; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD; TREATMENT OUTCOME; TUMOR CELL;

ADOLESCENT; ANTIGENS, CD44; BONE NEOPLASMS; CADHERINS; CELL ADHESION MOLECULES; CELL PROLIFERATION; CHILD; CHORDOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SPHENOID BONE; SPINAL NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 23944494306     PISSN: 10935266     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10024-005-1127-z     Document Type: Article

References (46)

1. Sibley RK, Day DL, Dehner LP. Metastasizing chordoma: a pathological and immunohistochemical study with review of the literature. Pediatr Pathol 1987;7:287-301.
2. Abenoza P, Sibley RK. Chordoma: an immunohistological study. Hum Pathol 1986;17:744-747.
3. Miettinen M. Chordoma. Antibodies to epithelial membrane antigen and carcinoembryonic antigen in differential diagnosis. Arch Pathol Lab Med 1984;108:891-924.
4. Horiguchi H, Sano T, Qian ZR, et al. Expression of cell adhesion molecules in chordomas: an immunohistochemical study of 16 cases. Acta Neuropathol 2004;107:91-96.
5. Mori K, Chano T, Kushima R, Hukuda S, Okabe H. Expression of E-cadherin in chordomas: diagnostic marker and possible role of tumor cell affinity. Virchows Arch 2002;440:123-127.
6. Rutherfoord GS, Davies AG. Chordomas - ultrastructure and immunohistochemistry: a report based on the examination of six cases. Histopathology 1987;11:775-787.
7. Miettinen M, Lehto VP, Dahl D, Virtanen I. Differential diagnosis of chordoma, chondroid, and ependymal tumors as aided by anti-intermediate filaments antibodies. Am J Pathol 1983;112:160-169.
8. Naka T, Oda Y, Iwamoto Y, Shinohara N, Chuman H, Fukui M, Tsuneyoshi M. Immunohistochemical analysis of E-cadherin, alpha-catenin, and neural cell adhesion molecules (NCAM) in chordoma. J Clin Pathol 2001;54:945-950.
9. Gotz G, Kasper M, Fisher G, Herken R. Intermediate filament typing of the human embryonic and fetal notochord. Cell Tissue Res 1995;280:455-462.
10. Takeichi M. Cadherin cell adhesion receptor as a morphologic regulator. Science 1991;251:1451-1455.
11. Behrens J, Mareel MM, Van Roy FM, Birchmeier W. Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol 1989;108:2435-2447.
12. Fahraeus R, Chen W, Trivedi P, Klein G, Obrink B. Decreased expression of E-cadherin and increased invasive capacity in EBV-LMP-transfected human epithelial and murine adenocarcinoma cells. Int J Cancer 1992;52:834-838.
13. Laskin WB, Miettinen M. Epithelial-type and neural-type cadherin expression in malignant noncarcinomatous neoplasms with epithelioid features that involve the soft tissues. Arch Pathol Lab Med 2002;126:425-431.
14. Naor D, Nedvetzki S, Golan I, et al. CD44 in cancer. Crit Rev Clin Lab Sci 2002;39:527-579.
15. Turley EA, Noble PW, Bourguignon LY. Signaling properties of hyaluronan receptors. J Biol Chem 2002;277:4589-4592.
16. Guler G, Sarac S, Uner, Karabulut E, Ayhan A, Ogawa H. Prognostic value of CD44 variant 6 in laryngeal epidermoid carcinomas. Arc Otolaryngol Head Neck Surg 2002;128:393-397.
17. Kim HS, Park YB, Oh JH, Jeong J, Kim CJ, Lee SH. Expression of CD44 isoforms correlates with the metastatic potential of osteosarcoma. Clin Orthop 2002;396:184-190.
18. Kawasaki H, Toyada M, Shinohara H, et al. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 2001;91:2026-2032.
19. Ali-Fehmi R, Qureshi F, Lawrence WD, Jacques SM. Apoptosis, proliferation, and expression of p53 and bcl-2 in endocervical glandular intraepithelial lesions and invasive endocervical adenocarcinoma. Int J Gynecol Pathol 2004;23:1-6.
20. Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, et al. Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, cyclin D1 and cyclin D3) and proliferation index (ki67-MIB1). Eur Urol 2004;45:606-612.
21. Staibano S, Franco R, Tranfa F, et al. Orbital rhabdomyosarcoma: relationship between DNA ploidy, p53, bcl-2, MDR-1 and K67 (MIB1) expression and clinical behavior. Anticancer Res 2004;24:249-257.
22. Roggendorf W, Schuster T, Peiffer J. Proliferative potential of meningiomas determined with the monoclonal antibody Ki-67. Acta Neuropathol 1987;73:361-364.
23. Ho DM, Hsu CY, Ting LT, Chiang H. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma. Cancer 2002;94:1538-1547.
24. Hoyt JW, Grown AM, Kim DK, Berger MS. Analysis of proliferative grade in glial neoplasm using antibodies to the Ki-67 antigen and PCNA in formalin fixed, deparaffinized tissues. J Neurooncol 1995;24:163-169.
25. Frank I, Cheville JC, Blute ML, et al. Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement. Cancer 2004;101:1803-1808.
26. Kilgore S, Prayson RA. Apoptotic and proliferative markers in chordomas: a study of 26 tumors. Ann Diagn Pathol 2002;6:222-228.
27. Holton JL, Steel T, Luxsuwong M, Crockard HA, Revesz T. Skull base chordomas: correlation to tumour doubling time with age, mitosis and Ki67 proliferation index. Neuropathol Apl Neurobiol 2000;26:497-503.
28. Naka T, Boltze C, Samii A, et al. Skull base and nonskull base chordomas: clinicopathologic and immunohistochemical study with special reference to nuclear pleomorphism and proliferative ability. Cancer 2003;98:1934-1941.
29. Matsuno A, Sasaki T, Nagashima T, et al. Immunohistochemical examination of proliferative potentials and the expression of cell cycle-related proteins of intracranial chordomas. Hum Pathol 1997;28:714-719.
30. Ariel IM, Verdu C. Chordoma: an analysis of twenty cases treated over a twenty-year span. J Surg Oncol 1975;7:27-44.
31. Congdon CC. Benign and malignant chordomas. A clinicoanatomic study of twenty-two cases. Am J Pathol 1952;28:793-821.
32. Heffelfinger MJ, Dahlin DC, MacCarty CS, Beabout JW. Chordomas and cartilaginous tumors at the skull base. Cancer 1973;23:410-420.
33. Higinbotham NL, Phillips RF, Farr HW, Hustsu HO. Chordoma. Thirty-five-year study at Memorial Hospital. Cancer 1967;11:1841-1850.
34. Kaneko Y, Sato Y, Iwaki T, Shin RW, Tateishi J, Fukui M. Chordoma in early childhood: a clinicopathological study. Neurosurgery 1991;29:442-446.
35. Tallini G, Dorfman H, Brys P, et al. Correlation between clinicopathological features and karyotype in 100 cartilaginous and chordoid tumours. A report from the chromosome and morphology (CHAMP) collaborative study group. J Pathol 2002;196:194-203.
36. Mirra JM, Della Rocca C, Nelson SD, Mertens F. Chordoma. In: Fletcher CDM, Unn KK, Mertens F, eds. World Health Organization Classfication of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone Lyon: IARC Press. 2002;316-317.
37. Scheil S, Bruderlein S, Liehr T, et al. Genome-wide analysis of 16 chordomas by comparative genomic hybridization and cytogenetics of the first human chordomas cell line, U-CH1. Genes Chromosomes Cancer 2001;32:203-211.
38. Gil Z, Fliss DM, Voskoboinik N, et al. Cytogenetic analysis of three variants of clival chordoma. Cancer Genet Cytogenet 2004;154:124-130.
39. Hruban RH, Traganos F, Reuter VE, Huvos AG. Chordomas with malignant spindle cell components. A DNA flow cytometric and immunohistochemical study with histogenetic implications. Am J Pathol 1990;137:435-447.
40. Spaar FW, Spaar U, Markakis E. DNA in chordomas of the clivus Blumenbachii. Neurosurg Rev 1990;13:219-229.
41. Berven S, Zurakowski D, Mankin HJ, Gebhardt MC, Springfield DS, Hornicek FJ. Clinical outcome in chordoma: utility of flow cytometry in DNA determination. Spine 2002;27:374-379.
42. Ammirati M, Bernardo A. Management of skull base chordoma. Crit Rev Neurosurg 1999;9:63-69.
43. Gay E, Sekhar LN, Rubinstein E, et al. Chordomas and chondrosarcomas of the cranial base: results and follow-up of 60 patients. Neurosurgery 1995;36:887-896.
44. Chambers PW, Schwinn CP. Chordoma: a clinicopathologic study of metastasis. Am J Anat 1979;128:193-224.
45. Forsyth PA, Cascino T, Shaw EG, et al. Intracranial chordomas: a clinicopathological and prognostic study of 51 cases. J Neurosurg 1993;78:741-747.
46. Hug EB, Loredo LN, Slater JD, et al. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. J Neurosurg 1999;91:432-439.